Nasdaq Stockholm Welcomes 2cureX to First North

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
524
Nasdaq Stockholm Welcomes 2cureX to First North

Stockholm, November 24, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in 2cureX AB’s shares (short name: 2CUREX) commenced today on Nasdaq First North in Stockholm. 2cureX belongs to the healthcare sector and is the 100th company to be admitted to trading on Nasdaq’s Nordic markets* in 2017.

Founded in 2006, 2cureX is a biotech company with a vision to improve treatment efficiency of cancer patients. The company has developed the IndiTreat method, an in-vitro test specialized in identifying and matching the individual cancer patient with the most effective medical treatment. The first IndiTreat product is directed towards colorectal cancer. 2cureX is headquartered in Copenhagen, Denmark. For more information, please visit www.2curex.com .

“We are excited about today’s successful listing on Nasdaq Fist North,” said Ole Thastrup, CEO of 2cureX. “We are looking forward to continuing our journey as a public company.”

“We welcome 2cureX to our European growth market, Nasdaq First North,” said Adam Kostyál, SVP and Head of European listings at Nasdaq. “2curex joins our strong and growing healthcare sector, and we look forward to stand by them on their journey as a public company.”

2cureX AB has appointed Sedermera Fondkommission AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius .

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact: Erik Granström +46 8 405 78 07 erik.granstrom@nasdaq.com  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Dynamics of Texas Instruments' Short Interest

Updated Category News Views 124

Delving into the Short Interest of Texas Instruments Texas Instruments TXN has recently seen a notable decrease in its short interest, which has fallen by 12.71% since the last report. As of the latest figures, the company reported that approximately 16.83 million shares have been sold short, representing around 2.06% of all shares available for trading. With these...

Continue Reading
Nuvoton Launches Revolutionary 1.7W Indigo Laser Diode

Updated Category News Views 343

Nuvoton Introduces an Innovative Indigo Laser Diode Nuvoton Technology Corporation Japan, widely known as NTCJ, has celebrated another milestone in laser technology with the introduction of their groundbreaking indigo semiconductor laser. This innovative product boasts an impressive optical output power of 1.7 W and operates at a wavelength of 420 nm, making it a...

Continue Reading
Exploring the Surge in Japanese Stocks Amid Political Changes

Updated Category News Views 121

Japanese Stocks Reach New Heights In recent times, Japanese stocks have soared to impressive new highs, buoyed by a combination of economic factors and political dynamics. A notable factor in this surge has been a weakening yen, coupled with increasing bond yields, coinciding with discussions around potential snap elections initiated by Prime Minister Sanae Takaichi....

Continue Reading
TGS Enhances Summer Operations in Northern Europe with Vessels

Updated Category News Views 183

TGS Expands Summer Operations in Northern Europe TGS, a renowned provider of energy data and intelligence, has reported an exciting summer season ahead in Northern Europe. This year, the company has not only increased its acquisition capacity but has also enhanced its operational efficiency with the deployment of four acquisition vessels in the region: three seismic...

Continue Reading
Zentalis Pharmaceuticals Welcomes James B. Bucher as CLO

Updated Category News Views 152

Zentalis Pharmaceuticals Strengthens Leadership with New Appointment In a significant move, Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on innovative therapies for cancer treatment, is thrilled to announce the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary. This strategic step comes...

Continue Reading